Assistant Professor Chungnam National University Yuseong-gu, Taejon-jikhalsi, Republic of Korea
Abstract:
Background: Fexuprazan, a novel potassium-competitive acid blocker, may benefit patients with gastric mucosal injury.
Objectives: To evaluate the efficacy and safety of fexuprazan in canine chronic gastritis. Animals: Twenty-seven client-owned dogs diagnosed with chronic gastritis.
Methods: A randomized active-controlled trial. Chronic gastritis was diagnosed in 20 dogs based on a comprehensive evaluation of clinical manifestations (CM), endoscopic findings (EF), and histopathological examination (HE). Patients were orally administered one of the following treatments once daily for four weeks: low-dose fexuprazan (Group 1; 0.5 mg/kg, n = 5), high-dose fexuprazan (Group 2; 0.5 mg/kg; n = 5), famotidine (Group 3; 0.5 mg/kg, n = 5), or esomeprazole (Group 4; 0.5 mg/kg, n = 5).
Results: Both fexuprazan groups (Group 1 and 2) and the groups treated with other medications (Group 3 and 4) showed significant post-treatment improvements in CM (P = 0.010; P = 0.048, respectively) and EF (P = 0.011; P = 0.019, respectively) scores. In each group, significant improvement in CM scores were observed in Group 1 (P = 0.042), and significant improvement in the EF scores were observed in Group 1 (P = 0.039) and Group 4 (P = 0.038). No significant differences in post-treatment CM (P = 0.080), EF (P = 0.515), and HE (P = 0.623) scores were identified between the groups. No significant adverse drug reactions were observed during the experimental period. Conclusions and Clinical Importance: Fexuprazan is considered a potential alternative to other acid-suppressing drugs and is regarded as safe for managing canine chronic gastritis.
